Angel Medical Systems said it’s closed a funding round worth $28 million for its AngelMed Guardian implant, designed to detect the early heart problems that can lead to heart attacks and alert patients to seek medical care.
The round included existing backers and a new contribution from SOAM Angel Partners, which added principal Dr. Victor Whitman to Angel Medical’s board, according to a press release.
The Guardian implantable device monitors patients for signs of ischemia, or lack of blood flow, in the heart and alerts the patient to seek medical care. The company said it plans to use the proceeds to finish up a Phase II pivotal trial for the device and to develop next-generation ischemia monitoring devices. Angel Medical will also spend some cash on extending its commercial reach in Europe and Brazil, where the AngelGuard system is already market-approved, according to the release.
Sign up to get our free newsletters delivered straight to your inbox
"We’ve made significant progress in our pivotal trial of the Guardian system, with more than 660 patients implanted with the device in the United States," CEO Dr. David Fischell said in prepared remarks. "This additional capital will enable us to continue study enrollment, and providing efficacy endpoints are met, file our premarket approval [application] in the coming year."
Last week Angel Medical revealed a $3.8 million tranche of the funding round.
CareStream wins DoD contract extension
CareStream Health landed a 4th yearlong contract extension on its $62.4 million deal with the U.S. Defense Dept. for imaging systems and components.
Read more
LensAR dials in on $5M
LensAR dialled up a $5 million funding round for its laser cataract surgery device from 3 unnamed investors.
Read more
Imaging Diagnostic pulls of 500-1 reverse split
Aiming to boost its share price, Imaging Diagnostic Systems (PINK:IMDSD) effected a 500-for-1 stock split Dec. 10, making each 500 shares of the common stock worth 1 share.
Read more
Covidien aims for Abbott’s share of enteral feeding market
Covidien (NYSE:COV) said it’s boosting production of its Kangaroo enteral feeding line after rival Abbott decided to get out of that market.
Read more
Analysts’ ups and downs
- Becton Dickinson & Co. (NYSE:BDX): Bank of America Merrill Lynch reinstated coverage on Becton, Dickinson and Co. (NYSE: BDX [FREE Stock Trend Analysis]) with an Underperform rating and $79.00 price target.
- Boston Scientific (NYSE:BSX): Barclays upgraded Boston Scientific (NYSE: BSX) from Equalweight to Overweight with a price target of $7.00 (from $6.
- Insulet (NSDQ:PODD): Jeffries raises price target from $23 to $25, maintains “buy” rating; Piper Jaffray upgraded Insulet Corporation (NASDAQ: PODD) from Neutral to Overweight with a price target of $27.00 (from $21.
- St. Jude Medical (NYSE:STJ): Leerink Swann reiterates “outperform” rating, ~$50 price target.
- Teleflex (NYSE:TFX): Credit Agricole upgrades from an “outperform” rating to a “buy” rating in a research note issued to investors on Monday. The firm currently has a $82.00 price target; Leerink Swann maintains “market perform” rating, ~$72 price target.
- Volcano (NSDQ:VOLC): Leerink Swann reiterates Outperform rating. $32 price target.
